News brief­ing: Dew­point scores an­oth­er Big Phar­ma deal, this time with Pfiz­er; Kite joins forces with Ox­ford Bio­Ther­a­peu­tics

Over the last 13 months, Dew­point Ther­a­peu­tics has scored big part­ner­ships with Bay­er and Mer­ck, aim­ing to pi­o­neer a new field of bi­ol­o­gy called bio­mol­e­c­u­lar con­den­sates. On Wednes­day, the biotech reeled in an­oth­er big phar­ma deal.

Dew­point agreed to a re­search col­lab­o­ra­tion with Pfiz­er on Wednes­day for the de­vel­op­ment of ther­a­pies for my­oton­ic dy­s­tro­phy type 1, a rare ge­net­ic dis­or­der. The deal can be worth up to $239 mil­lion when ac­count­ing for all mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER